How much has Thermo Fisher Scientific raised?
Thermo Fisher Scientific is not venture-backed. As of June 2026 it was a public company trading as NYSE: TMO, with an approximate ~$175B market capitalization and $44.56B of 2025 revenue.
- Public status
- NYSE: TMO
- Market cap
- ~$175B (Jun 2026)
- Revenue
- $44.56B 2025
- Funding type
- Public markets
- First raised
- Not VC disclosed
- Seller signal
- Enterprise healthcare buyer
Thermo Fisher Scientific's capital history
Thermo Fisher Scientific's capital history is public-company funding, operating cash flow, acquisitions, and market access rather than startup rounds.
- 2006Company foundedThermo Fisher Scientific begins the business that later scales into a public healthcare company.
- Public listingNYSE: TMO public-market accessPublic equity and debt-market access replace startup-style venture rounds as the relevant capital lens.
- M&A eraPortfolio expansionAcquisitions, divestitures, and internal reinvestment become important capital-allocation tools.
- 2025$44.56B revenueThermo Fisher Scientific reports $44.56B of revenue for 2025.
- Jun 2026~$175B market capThermo Fisher Scientific trades as NYSE: TMO with large public-market buying capacity.
Sources:Thermo Fisher Scientific annual reportsNYSE: TMO market data
How much has Thermo Fisher Scientific raised in total?
Thermo Fisher Scientific does not have a meaningful disclosed venture-funding total. The company should be evaluated through public equity, operating cash flow, debt capacity, acquisitions, divestitures, and retained earnings rather than Seed, Series A, or late-stage venture rounds.
Who are Thermo Fisher Scientific's investors?
The relevant investors are public-market shareholders, bondholders where applicable, index funds, active healthcare investors, and strategic capital allocators inside the company. Their focus is durable revenue, margins, cash conversion, regulatory risk, reimbursement exposure, and management's ability to deploy capital at attractive returns.
Why does Thermo Fisher Scientific's valuation move?
Thermo Fisher Scientific's valuation moves with growth, margins, cash flow, reimbursement or pricing pressure, regulatory developments, product cycles, acquisition execution, labor and supply costs, and investor confidence in management's outlook. Healthcare buyers can still spend during turbulent markets, but approvals become more tied to measurable savings and risk control.
Is Thermo Fisher Scientific profitable, and will it IPO?
Thermo Fisher Scientific is already public. Profitability should be assessed from its filings and earnings releases rather than IPO readiness; the practical question is how much cash and management attention can be allocated to new vendors, systems, facilities, clinical programs, or commercial expansion.
What does Thermo Fisher Scientific's funding mean if you sell into them?
The company has enterprise-scale budget capacity, but procurement is mature and evidence-driven. Sellers should expect security review, compliance review, legal negotiation, business-unit sponsorship, and a requirement to prove value in patient outcomes, operating efficiency, revenue capture, supply reliability, or risk reduction.
As of June 2026.Sources:Thermo Fisher Scientific resultsThermo Fisher Scientific annual reportsNYSE: TMO market data
Thermo Fisher Scientific — frequently asked questions
